Physician profile
Scott H Bailey
NPI 1437114873
$2,307.05
in general payments reported to CMS, 2019-2025
23 companies · $25.29 in 2025
The $25.29 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $677 · 2020: $281 · 2021: $52.02 · 2022: $247 · 2023: $549 · 2024: $476 · 2025: $25.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,050.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $401.09 | 2019-2025 | Veozah, Cresemba, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $371.70 | 2019-2024 | |
| Abbvie INC. | $312.17 | 2019-2024 | Orilissa, Lo Loestrin Fe, Liletta |
| Coopersurgical, INC. | $225.26 | 2019-2023 | Paragard T 380a, Endosee |
| Therapeuticsmd, INC. | $195.50 | 2019-2022 | |
| Lupin INC. | $123.22 | 2019-2020 | |
| Exact Sciences Corporation | $100.00 | 2024 | Cologuard Collection Kit |
| Exeltis, USA INC. | $97.35 | 2019-2024 | Slynd |
| Sumitomo Pharma America, INC. | $92.77 | 2023-2024 | Myfembree, Gemtesa |
| Vertical Pharmaceuticals, LLC | $87.02 | 2019 | |
| Mylan Pharmaceuticals INC. | $55.37 | 2019-2020 | |
| Pfizer INC. | $40.19 | 2024 | |
| Mayne Pharma Commercial LLC | $25.03 | 2023 | |
| Mission Pharmacal Company | $24.98 | 2019 | |
| Organon LLC | $24.19 | 2023 | Nexplanon |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $23.83 | 2023 | Truclear |
| Roche Diagnostics Corporation | $18.31 | 2019 | |
| Ibsa Pharma INC. | $17.79 | 2023 | Tirosint, Licart |
| Takeda Pharmaceuticals U.S.A., INC. | $16.64 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.92 | 2019 | |
| Merck Sharp & Dohme LLC | $14.32 | 2019 | |
| Agile Therapeutics, INC. | $13.49 | 2022 | |
| Avion Pharmaceuticals | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.